We have suggested that the anti-obesity effect of ZAG may be due to central activation of the sympathetic nervous system, rather than direct activation of the β3-adrenoceptor and this is why its anti-obesity effect is blocked by propranolol (Wargent et al., 2013). Here, AZGP1 is linked to obesity due to melanocortin 4 receptor deficiency.